Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (74.1%), Europe (17%) and other (8.9%).

Number of employees : 11 800 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Innovative Medicines22,12799.6%22,449100.6% +1.46%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States16,26973.2%16,64574.6% +2.31%
Europe4,00618%3,81117.1% -4.87%
Other International1,8528.3%1,9938.9% +7.61%
Managers
NameAgeSinceTitle
Daniel O'Day552019Chairman & Chief Executive Officer
Andrew D. Dickinson492019Chief Financial Officer
William A. Lee, Dr.642015Executive Vice President-Research
Merdad V. Parsey, Dr.-2019Chief Medical Officer
George Pratt Shultz, Dr.962006Director-Emeritus
Gayle Edlund Wilson762001Independent Director
John Francis Cogan, Dr.712013Lead Independent Director
Richard J. Whitley, Dr.732008Independent Director
Kevin E. Lofton642009Independent Director
Per Wold-Olsen722010Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,253,724,370 1,248,777,574 99.6% 0 0.0% 99.6%
Shareholders
NameEquities%
Capital Research & Management Co. (Global Investors) 125,356,882 10.00%
The Vanguard Group, Inc. 98,734,165 7.88%
Putnam LLC 83,388,336 6.65%
Capital Research & Management Co. 64,780,000 5.17%
SSgA Funds Management, Inc. 58,026,712 4.63%
Capital Research & Management Co. (International Investors) 57,143,147 4.56%
Capital Research & Management Co. (World Investors) 43,503,830 3.47%
BlackRock Fund Advisors 32,981,364 2.63%
Geode Capital Management LLC 19,665,435 1.57%
Northern Trust Investments, Inc.(Investment Management) 16,081,206 1.28%
Holdings
NameEquities%Valuation
Galapagos NV (GLPG) 16,707,47725.6%2,374,553,009 USD
Allogene Therapeutics, Inc. (ALLO) 7,486,6895.37%282,323,042 USD
Arcus Biosciences, Inc. (RCUS) 8,163,02912.6%139,914,317 USD
Agenus Inc. (AGEN) 11,111,1116.06%44,444,444 USD
HOOKIPA Pharma Inc. (HOOK) 1,667,2687.64%15,789,028 USD
Sierra Oncology, Inc. (SRRA) 348,0173.35%3,713,341 USD
Markets and indexes
-
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 100, S&P 500, Stoxx Americas 100, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  GILD:US
- Reuters Code :  GILD.O
- Datastream Code :  @GILD
Company contact information
Gilead Sciences, Inc.
333 Lakeside Drive
CA 94404 San Mateo, California


Phone : +1 650 574 3000
Fax : +1 650 578 9264
Internet : http://www.gilead.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Gilead Sciences, Inc.
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-7.73%75 173
REGENERON PHARMACEUTICALS56.00%61 638
VERTEX PHARMACEUTICALS-5.39%53 956
WUXI APPTEC CO., LTD.59.09%37 810
BEIGENE, LTD.81.76%27 304
GENMAB A/S48.16%22 791
BIONTECH SE144.78%19 752
HUALAN BIOLOGICAL ENGINEERING INC.91.99%14 110
MYOKARDIA, INC.205.96%11 891
ARGENX SE45.96%11 726
SAREPTA THERAPEUTICS, INC.7.42%10 882
NEUROCRINE BIOSCIENCES, INC.-6.09%9 413
MIRATI THERAPEUTICS, INC.52.63%8 760
ASCENDIS PHARMA A/S14.01%8 439
EXELIXIS, INC.24.29%6 767
ACCELERON PHARMA INC.104.47%6 493
BIOCON LIMITED37.06%6 453
ARROWHEAD PHARMACEUTICALS, INC.-6.83%6 045
PEPTIDREAM INC.-15.09%5 700
ULTRAGENYX PHARMACEUTICAL INC.113.65%5 529
DENALI THERAPEUTICS INC.141.56%5 020